| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | plyA |
| Uniprot No | B8NE46 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-321aa |
| 氨基酸序列 | APTKTIGKRAAITDVAHGYASQNGGTTGGAGGTTTTVSSYAQFTEAVSSDDAKIVIVDGTITETADQVKVGSNTSIIGKDANAILEGFGLLVKEKENVIIRNLGVKKVLADNGDAIGVQYSNNVWIDHCDVSSDRDHDKDYYDGLIDLTHAADYVTVSNTFVHDHWKAMLFGHSDSNGDEDTGHLRITVNNNYLNNLNSRGPSFRFGTGHLYNNYYLDVSDGINTRQGAQLLVEGNVWSGGKKPLYSTDDGYAVARDNDFGDGENTAPEGTLTSVPYEYDLLAASAVKDAVVGTAGQTLTF |
| 预测分子量 | 36.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条关于plyA重组蛋白的参考文献及其摘要概括：
---
1. **文献名称**: *Heterologous expression and functional characterization of PlyA, a bacteriophage-encoded endolysin against Streptococcus pneumoniae*
**作者**: Rodríguez-Cerrato V, et al.
**摘要**: 研究在大肠杆菌中重组表达了肺炎链球菌噬菌体裂解酶PlyA，证实其能有效裂解多种肺炎链球菌菌株，并验证其作为抗菌剂的潜力。
---
2. **文献名称**: *Crystal structure and biochemical characterization of the recombinant PlyA protein from Bacillus phage*
**作者**: Xu Q, et al.
**摘要**: 解析了枯草芽孢杆菌噬菌体来源的PlyA重组蛋白的晶体结构，揭示了其底物结合域和催化机制，并通过酶活实验证明其对肽聚糖的高效水解能力。
---
3. **文献名称**: *Antibiofilm activity of recombinant PlyA enzyme against Staphylococcus aureus biofilms*
**作者**: Gupta R, et al.
**摘要**: 通过重组表达纯化PlyA蛋白，证明其能显著破坏金黄色葡萄球菌生物被膜，并增强传统抗生素的杀菌效果，提出其在抗生物膜治疗中的应用前景。
---
注：以上文献为示例性质，实际引用时建议通过PubMed或Web of Science核对具体信息。
**Background of PlyA Recombinant Protein**
PlyA, or pneumolysin A, is a pore-forming cytolysin originally identified in *Streptococcus pneumoniae*, a pathogenic bacterium responsible for respiratory infections and invasive diseases. As a member of the cholesterol-dependent cytolysin (CDC) family, PlyA plays a critical role in bacterial virulence by disrupting host cell membranes, facilitating immune evasion, and promoting tissue invasion. Its ability to lyse eukaryotic cells and activate inflammatory pathways has made it a key target for both vaccine development and antimicrobial research.
Recombinant PlyA (rPlyA) is produced through genetic engineering, typically by cloning the *plyA* gene into expression systems like *E. coli* or yeast. This allows large-scale production of purified, biologically active protein for research and therapeutic applications. Recombinant technology enables modifications to reduce toxicity (e.g., creating non-cytolytic mutants) while retaining immunogenic epitopes, which is valuable for vaccine candidates. For instance, detoxified PlyA variants are being explored as components of protein-based vaccines against pneumococcal infections.
Beyond vaccinology, rPlyA serves as a tool to study host-pathogen interactions, membrane biology, and immune responses. Its pore-forming mechanism provides insights into cell death pathways and intracellular signaling. Additionally, engineered PlyA derivatives have potential applications in biotechnology, such as targeted drug delivery systems leveraging its membrane-binding specificity.
Despite its pathogenic origin, PlyA’s conserved structure and functional versatility underscore its significance in both basic science and translational medicine, bridging microbiology, immunology, and bioengineering.
×
